Ligand Pharmaceuticals Inc. reports developments in its biopharmaceutical royalty aggregation and technology-licensing business. The company partners with pharmaceutical and biotechnology companies, funds late-stage clinical development programs in exchange for long-term economic interests, and manages royalty interests across development- and commercial-stage therapeutic assets.
Recurring LGND news includes operating and financial results, royalty revenue drivers, material agreements, capital-structure updates, and partner clinical or regulatory events tied to products in the portfolio. Company updates also cover proprietary technologies such as Captisol® and NITRICIL™, business-development activity, and portfolio assets such as FILSPARI® where Ligand has an economic interest.
Ligand (Nasdaq: LGND) said senior management will attend three investor conferences in March 2026, offering one-on-one meetings and two public presentations. Presentations are scheduled at the 38th Annual ROTH Conference on March 23, 2026 at 1:00 p.m. PT and the Nordic-American Healthcare Conference on March 25, 2026 at 3:45 p.m. ET. Investors may request one-on-one meetings through their Leerink, ROTH, or NAHC representative.
Ligand (Nasdaq: LGND) reported strong fourth-quarter and full-year 2025 results with total revenues of $59.7M (Q4) and $268.1M (2025). Full-year royalty revenue grew 48%, to $161.0M. GAAP net income was $124.5M for 2025; core adjusted net income was $165.1M or $8.13 per diluted share. The company reaffirmed 2026 guidance: $245M–$285M revenue and adjusted EPS of $8.00–$9.00. Cash, cash equivalents and short-term investments totaled $733.5M as of December 31, 2025.
Key commercial and clinical updates include regulatory filings, positive Phase 3/2 readouts across partnered programs, and recent transactions affecting contract revenue and royalties.
Ligand (Nasdaq: LGND) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, and will host a conference call at 8:30 a.m. ET with live webcast and replay available.
The company described its asset-light royalty and technology licensing model, highlighted Captisol and NITRICIL platforms, and urged investors to monitor its investor relations website and X for material disclosures.
Ligand (Nasdaq: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 10:00 a.m. Eastern Time.
Management is also scheduled for one-on-one investor meetings during the conference; investors should contact their Oppenheimer representative to arrange meetings.
Ligand (Nasdaq: LGND) hosted an Investor Day on Dec 9, 2025 and introduced 2026 guidance. The company forecasted 2026 total revenue $245m–$285m, including royalty revenue $200m–$225m (about a 40% increase vs 2025) and core adjusted EPS $8.00–$9.00. Ligand reiterated 2025 guidance of core revenue $225m–$235m and outlined a 5-year royalty receipts outlook of ≥23% CAGR. Management highlighted drivers including Filspari, Ohtuvayre, Capvaxive, Qarziba, and Zelsuvmi, noted $1 billion of deployable capital for royalty investments, and described Captisol and NITRICIL as royalty-generating platforms. The Investor Day was webcast live with presentation replay available on the company website.
Ligand (Nasdaq: LGND) reported Q3 2025 revenue $115.5M (up 123% YoY) and raised 2025 core revenue guidance to $225M–$235M and core adjusted EPS to $7.40–$7.65. Q3 royalties were $46.6M (up 47% YoY). GAAP net income was $117.3M or $5.68 per diluted share; adjusted net income was $63.8M or $3.09 per diluted share. Cash, cash equivalents and short-term investments totaled $664.5M as of Sept 30, 2025. Company completed a $460M 2030 convertible notes offering (net proceeds ~$445M) and recognized a $28.6M gain from the Pelthos sale and $24.5M from a Zelsuvmi out-license.
Ligand (Nasdaq: LGND) announced CEO Todd Davis and CFO Tavo Espinoza will attend three investor conferences in November 2025.
Key dates: UBS Global Healthcare Conference one-on-one meetings on November 10, 2025; Stifel 2025 Healthcare Conference fireside chat on November 12, 2025 at 8:40 a.m. ET; Southwest IDEAS 2025 Investor Conference presentation on November 20, 2025 at 1:20 p.m. CT. Management will host one-on-one investor meetings; investors should contact their UBS or Stifel representative to arrange meetings.
Ligand (Nasdaq: LGND) will report third quarter 2025 financial results on Thursday, November 6, 2025. A conference call will begin at 8:30 AM Eastern Time to discuss results and provide a business update.
Investors can join by phone in the U.S. and Canada at (800) 715-9871 or internationally at (646) 307-1963 using Conference ID 3661098. A live webcast and replay will be available via the company webcast link.
Ligand (Nasdaq: LGND) will hold its annual Investor Day on December 9, 2025 in New York City at The Harvard Club from 10:30 a.m. to 12:00 p.m. ET. Management presentations will include CEO Todd Davis and CFO Tavo Espinoza and will cover the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook.
Guest speaker Scott Plesha, CEO of partner Pelthos Therapeutics, will discuss the recent launch of ZELSUVMI (berdazimer) topical gel 10.3%, described as the first FDA-approved at-home treatment for molluscum contagiosum. A live webcast and replay will be available on Ligand’s investor relations website, and investors can register for the event online.
Ligand (Nasdaq: LGND) said partner SQ Innovation received FDA approval on October 9, 2025 for Lasix ONYU (furosemide injection), a drug‑device combo enabling subcutaneous, at‑home treatment of edema in adults with chronic heart failure.
Lasix ONYU is a high‑concentration furosemide formulation (80mg/2.67mL; 30mg/mL) using Captisol and pairs with a reusable Infusor (48 treatments) plus a sterile single‑use cartridge. Captisol is cited as a key enabler and this is the 17th Captisol‑enabled product. Ligand holds exclusive Captisol license/supply terms with SQ Innovation signed in 2019 and will receive milestone payments, a low‑single‑digit royalty, and material sales revenue. SQ Innovation expects product availability in Q4 2025.